Intranasal Glutathione in Parkinson's Disease

Inclusion Criteria: 1. Diagnosis of Parkinson's Disease made by neurologist within previous 10 years 2. Modified Hoehn and Yahr Stage \<3 3. Age \>20 4. Subjects must be able to attend study visits at screening, baseline, weeks 4, 8, 12, 16 5. Subjects must be able to demonstrate self-administration of study medication or have active caregiver who can administer daily. 6. Dose and frequency of all pharmaceutical medications must be stable for one month prior to enrollment. 7. Diet, exercise and supplementation must be kept constant throughout participation in study 8. Ability to read and speak English Exclusion Criteria: 1. Dementia as evidenced by Montreal Cognitive Assessment (MoCA) \<24 2. Diseases with features common to Parkinson's Disease (eg. essential tremor, multiple system atrophy, progressive supranuclear palsy) 3. Epilepsy 4. History of stroke, CVA 5. Elevated levels of ALT, AST, BUN or creatinine 6. Chronic sinusitis as defined by SNOT-20 score \>1.0 on items 1-10. 7. Presence of other serious illness 8. History of brain surgery 9. History of structural brain damage 10. History of intranasal telangiectasia 11. Supplementation with glutathione and agents shown to increase glutathione will not be permitted and will require a 90 day washout period. 12. Pregnant or at risk of becoming pregnant.